

June 10, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure of Related Party Transactions for the half year ended 31st March, 2022

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions for the half year / six months ended 31st March, 2022.

The same is also being made available on the website of the Company at www.glenmarkpharma.com

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited


Harish Kuber
Company Secretary & Compliance Officer



Encl: As above

85	Glenmark Pharmaceuticals Limited	Glenmark Therapeutics Inc.	Wholly Owned Subsidiary	Receivable			3.94	3.94										
86	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals SK, s.r.o.	Wholly Owned Subsidiary	Payable			0.01	0.01										
87	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals SP Zoo	Wholly Owned Subsidiary	Payable			0.15	0.15										
88	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Thailand) Co. Ltd.	Wholly Owned Subsidiary	Receivable			43.23	24.39										
89	Glenmark Pharmaceuticals Limited	Glenmark Uruguay S.A.	Wholly Owned Subsidiary	Payable			741.18	754.98										
90	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Colombia Ltda.	Wholly Owned Subsidiary	Receivable			59.47	47.60										
91	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Kenya Ltd.	Wholly Owned Subsidiary	Receivable			985.93	1,010.67										
92	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Mexico S.A. DE C.V.	Wholly Owned Subsidiary	Receivable			245.73	200.13										
93	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Egypt S.A.E.	Wholly Owned Subsidiary	Receivable			143.98	152.65										
94	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Canada Inc.	Wholly Owned Subsidiary	Receivable			378.88	173.71										
95	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals B.V.	Wholly Owned Subsidiary	Payable			0.01	0.01										
96	Glenmark Pharmaceuticals Limited	Glenmark Specialty S.A.	Wholly Owned Subsidiary	Receivable			3,488.55	3,587.02										
97	Glenmark Pharmaceuticals Limited	Glenmark Ukraine LLC	Wholly Owned Subsidiary	Receivable			270.45	314.04										
98	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Ecuador S.A.	Wholly Owned Subsidiary	Receivable			127.15	84.74										
99	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Singapore	Wholly Owned Subsidiary	Payable			52.06	49.69										
100	Glenmark Pharmaceuticals Limited	Ichnos Sciences Inc.	Wholly Owned Subsidiary	Receivable			2.69	5.48										
101	Glenmark Pharmaceuticals Limited	Glenmark Lifesciences Ltd.	Subsidiary	Payable			2,656.46	2,697.43										

Notes:

- 1 All Related Party Transactions entered during the period were in ordinary course of the business and on arm's length basis.
- 2 Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.
- 3 Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.
- 4 Balances have been aggregated entity wise for all type of transactions and shown as net receivable/(payable)
- 5 As per the guidance note for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- 6 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors, as applicable, for financial year 2021-22.